Table 1

Published reports of adults and children with ITP treated with rituximab

Author, YPatientsResponse to treatment, N (%)
Complete, > 100 × 109/L or > 150 × 109/L*Partial, 50-100 × 109/L or 50-150 × 109/L*None, < 50 × 109/LTotal N response
Published reports of adults with ITP treated with rituximab
    Braendstrup et al, 20055356 (17)6 (17)23 (66)12 (34)
    Cooper et al, 200465718 (32)13 (23)26 (45)31 (54)
    Giagounidis et al, 20027125 (42)4 (33)3 (25)9 (75)
    Narang et al, 2003863 (50)2 (33)1 (17)5 (83)
    Penalver et al, 200698338 (46)7 (8)38 (46)45 (54)
    Saleh et al, 200010132 (15)1 (8)10 (77)3 (23)
    Narat et al, 20051164 (67)1 (17)1 (17)5 (83)
    Shanafelt et al, 200312115 (45)1 (10)5 (45)6 (55)
    Wang et al, 20051344 (100)0 (0)0 (0)4 (100)
    Zaja et al, 200314§156 (40)2 (13)7 (47)8 (53)
    Alasfoor et al, 2009151210 (83)2 (17)0 (0)12 (100)
    Medeot et al, 2008162614 (54)4 (15)8 (31)18 (69)
    Parodi et al, 20091811 (100)0 (0)0 (0)1 (100)
    Godeau et al, 2008276021 (35)15 (25)24 (40)36 (60)
    Garcia-Chavez et al, 200728185 (28)5 (28)8 (44)10 (56)
    Pasa et al, 200929172 (12)8 (47)7 (41)10 (59)
Total376144/376 (38)71/376 (19)161/376 (43)215/376 (57)
Published reports of children with ITP treated with rituximab
    Bennettt et al, 20064368 (22)3 (8)25 (70)11 (31)
    Mueller et al, 200917 (follow-up study)
    Penalver et al, 2006963 (50)1 (17)2 (33)4 (66)
    Wang et al, 2005132415 (63)2 (8)7 (29)17 (71)
    Alasfoor et al, 20091521 (79)0 (14)1 (7)1 (93)
    Parodi et al, 2009184825 (52)8 (17)15 (31)33 (69)
Total11652/116 (45)14/116 (12)50/116 (43)66/116 (57)
  • ITP indicates immune thrombocytopenic purpura.

  • * Complete and partial response criteria were defined in the original reports for each patient series listed.

  • Patients from Stasi et al51 included here.

  • Actual patient count is 12, but one patient died only 6 days posttreatment and was removed from analysis.

  • § Patients from Zaja et al52 included here.